ENTERO: strong first half lifts odds of beating FY27 guidance
ENTERO reported H1 revenue up 35% year on year, wider margins and stronger MedTech contribution; management expects FY27 to beat initial guidance.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, ENTERO's revenue for the first half rose 35% year on year. The company points to expanding margins and a bigger contribution from its MedTech business.
Management now expects growth and profitability in FY27 to come in above its initial guidance. It is keeping its target of converting 50% of EBITDA into operating cash flow.
why it matters
For investors, the combination of faster revenue growth and higher margins supports expectations for the full year, not just the first six months. Keeping the EBITDA-to-cash-flow target unchanged suggests the company is not sacrificing cash generation for growth.
market impact
ENTERO shares: strong first-half results support the stock
- ENTERO shares pressure up — faster revenue growth and wider margins improve earnings expectations
tags
instruments
sources
- ENTERO: H1 growth and margin gains support confidence in beating FY27 guidance — TradingView, 5 November 2026 at 10:21 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗